Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Clinical Infectious Diseases · 05.02.2025 · 80 (1) · 223-227
DOI: 10.1093/cid/ciae465 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Infectious Diseases, online erschienen am 26.09.2024. Verfasst von Youyi Fong und 43 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibodies, Viral, COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS, BLRD VA.
Abstract (Originalsprache)
For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington, USA.
- Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- Frederick National Laboratory for Cancer Research, Clinical Monitoring Research Program Directorate, Frederick, Maryland, USA.
- Hope Clinic, Department of Medicine, Division of Infectious Diseases, Emory University, Decatur, Georgia, USA.
ORCID-Profile: Peter B Gilbert
Förderung
- National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- BLRD VA
- CSRD VA
- CLC NIH HHS
- NCI NIH HHS
- Administration for Strategic Preparedness and Response
- Sanofi
Zitieren
APA
Fong, Y., Dang, L., Zhang, B., Fintzi, J., Chen, S., Wang, J., Rouphael, N. G., Branche, A. R., Diemert, D. J., Falsey, A. R., Losada, C., Baden, L. R., Frey, S. E., Whitaker, J. A., Little, S. J., Kamidani, S., Walter, E. B., Novak, R. M., Rupp, R., …, & Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team (2025). Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clinical Infectious Diseases, 80(1), 223-227. https://doi.org/10.1093/cid/ciae465
Vancouver
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, et al. Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clinical Infectious Diseases. 2025;80(1):223-227. doi:10.1093/cid/ciae465
BibTeX
@article{Fong2025,
author = {Fong, Youyi and Dang, Lauren and Zhang, Bo and Fintzi, Jonathan and Chen, Shiyu and Wang, Jing and Rouphael, Nadine G and Branche, Angela R and Diemert, David J and Falsey, Ann R and Losada, Cecilia and Baden, Lindsey R and Frey, Sharon E and Whitaker, Jennifer A and Little, Susan J and Kamidani, Satoshi and Walter, Emmanuel B and Novak, Richard M and Rupp, Richard and Jackson, Lisa A and Yu, Chenchen and Magaret, Craig A and Molitor, Cindy and Borate, Bhavesh and Babu, Tara M and Kottkamp, Angelica C and Luetkemeyer, Anne F and Immergluck, Lilly C and Presti, Rachel M and Bäcker, Martín and Winokur, Patricia L and Mahgoub, Siham M and Goepfert, Paul A and Fusco, Dahlene N and Atmar, Robert L and Posavad, Christine M and Mu, Jinjian and Makowski, Mat and Makhene, Mamodikoe K and Nayak, Seema U and Roberts, Paul C and Follmann, Dean and Gilbert, Peter B and Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team, Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team},
title = {Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {80},
number = {1},
pages = {223--227},
doi = {10.1093/cid/ciae465}
}
EUVIMED